Multi-Mode Micro-Plate Detection Platform
Contracting Office Address
Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E638, Bethesda, MD 20892, UNITED STATES
This is a combined synopsis/solicitation for commercial items, prepared in accordance with format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation: No. NCI-N02RC73802-53 includes all applicable provisions and clauses in effect through FAR Federal Acquisition Circular (FAC) 2005-95, simplified procedures for commercial items.
This acquisition will be conducted under the procedures for acquiring commercial items authorized in FAR Part 12 and under the authority to use simplified procedures for commercial requirements as provided in FAR 13.501.
This requirement is assigned North American Industry Classification System (NAICS) code 334510 with a size standard of 1,250 employees.
Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract.
Delivery will be within 30 days of receipt of purchase order to the following address:
10 Center Drive Building 10, Bethesda, MD 20892
It has been determined there are no opportunities to acquire green products or services for this procurement.
The National Cancer Institute (NCI) plans to procure one (1) Brand Name or Equal SpectraMax iD3 Multi-Mode Microplate Platform (including: reader, pc, notebook bundle), in support of the Center for Cancer Research (CCR), Women's Malignancies Branch (WMB).
Department Background and Purpose
The Women's Malignancies Branch (WMB) of CCR, NCI is fully engaged in developing targeted therapeutics for all types of cancer affecting women. Ovarian, Cervical and Breast cancer affect hundreds of thousands of women each year. Therefore, it is clearly of benefit to all section of the WMB, the NCI and the NIH, and hence to the government, to facilitate
studies that will enable discovery of treatment and prevention of these types of cancer. The purchase and operation of a multi-mode microplate platform will advance the governmental mission of the Women's Malignancies Branch to promote the health and well-being of all women.
The current focus of the WMB laboratory is set up for the development of more effective therapy by identifying molecular pathways that are critical to the growth and survival of cancer cells and on targeting these pathways as treatment. The laboratory studies are aimed at a better understanding of signal transduction pathways that regulate growth and programmed cell death in epithelial cancer cells in order to develop more effective therapies. There are currently two projects in need of the required equipment. The first is a basic project that investigates the regulation of receptor tyrosine kinase (RTK) function by Cbl proteins in epithelial cells. The second is a translational project that investigates the manipulation of signal transduction and apoptosis pathways as a means to
kill breast cancer cells.
Salient Characteristics
The salient characteristics that apply to the SpectraMax iD3 Multi-Mode Microplate Platform are as follows:
• The reader must have the ability to read UV/VIS Absorbance, top/bottom read Fluorescence and Luminescence in microplate (6-384 well) format and uses monochromators for all the above including fluorescence
• No filters are required which increase the reliability of the data while decreasing the background effects.
• The plate-reader must measure absorbance, fluorescence, and luminescence with a single lamp.
• The reader also must have a touch screen that can connect to the NCI network so that each user can simply send their data results to their own desktop without any need for transfer to a server or a flash drive.
PAYMENT
Payment shall be made upon the delivery and acceptance of all required items listed.
CONTRACT CLAUSES/PROVISIONS
The following Federal Acquisition Regulation and Health & Human Services Acquisition
Regulation Provisions/Clauses apply to this acquisition:
FAR 52.252-2 CLAUSES INCORPORATED BY REFERENCE (FEB 1998)
This contract incorporates one or more clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make their full text available. Also, the full text of a clause may be accessed electronically at this/these address(es): http://www.acquisition.gov/far/ and/or http://www.hhs.gov/policies/hhsar/.
FAR 52.211-6 BRAND NAME OR EQUAL (AUG 1999)
FAR 52.212-1 INSTRUCTIONS TO OFFERORS-COMMERCIAL ITEMS (JAN 2017)
FAR 52.212-3 OFFEROR REPRESENTATIONS AND CERTIFICATIONS-
COMMERCIAL ITEMS (JAN 2017)
FAR 52.212-4 CONTRACT TERMS AND CONDITIONS-COMMERCIAL ITEMS (JAN
2017)
FAR 52.212-5 CONTRACT TERMS AND CONDITIONS REQUIRED TO IMPLEMENT
STATUTES OR EXECUTIVE ORDERS-COMMERCIAL ITEMS (JAN
2017). The following FAR clauses cited in paragraph (b) of the clause at FAR
52.212-5 are also applicable to this acquisition:
FAR Clause 52.203-6 Restrictions on Subcontractor Sales to the Government
FAR Clause 52.219-4 Notice of Price Evaluation Preference for HUBZone Small
Business Concerns.
FAR Clause 52.219-6 Notice of Total Small Business Set-Aside
FAR Clause 52.219-8 Utilization of Small Business Concerns
FAR Clause 52.219-28 Post Award Small Business Program Representation
FAR Clause 52.222-3 Convict Labor
FAR Clause 52.222-19 Child Labor-Cooperation with Authorities and Remedies
FAR Clause 52.222-21 Prohibition of Segregated Facilities
FAR Clause 52.222-26 Equal Opportunity
FAR Clause 52.222-35 Equal Opportunity for Special Disabled Veterans, Veterans of
the Vietnam Era, and Other Eligible Veterans
FAR Clause 52.222-36 Affirmative Action for Workers with Disabilities
FAR Clause 52.222-37 Employment Reports of Special Disabled Veterans, Veterans of the Vietnam Era, and Other Eligible Veterans
FAR Clause 52.222-39 Notification of Employee Rights Concerning Payment of Union
Dues or Fees
FAR Clause 52.225-5 Trade Agreements
FAR Clause 52.225-13 Restrictions on Certain Foreign Purchases
Far Clause 52.232-33 Payment by Electronic Funds Transfer-System for Award
Management
FAR Clause 52.247-64 Preference for Privately Owned U.S.-Flag Commercial Vessels
HHSAR 352.203-70 ANTI-LOBBYING (DEC 2015)
Pursuant to the current HHS annual appropriations act, Public Law 112-74, except for normal and recognized executive-legislative relationships, the Contractor shall not use any HHS contract funds for:
(a)Publicity or propaganda purposes;
(b)The preparation, distribution, or use of any kit, pamphlet, booklet, publication, electronic communication, radio, television or video presentation designed to support or defeat the enactment of legislation before the Congress or any State or local legislature or legislative body, except in presentation to the Congress or any State or local legislature itself; or designed to support of defeat any proposed or pending regulation, administrative action, or order issued by the executive branch of any State or local government, except in presentation to the executive branch of any State or local government itself; or
(c)Payment of salary or expenses of the Contractor, or any agent acting for the Contractor, related to any activity designed to influence the enactment of legislation, appropriations regulation, administrative action, or Executive order proposed or pending before the Congress or any State government, State legislature or local legislature or legislative body, other than for normal and recognized executive-legislative relationships or participation by an agency or officer of a State, local or tribal government is policymaking and administrative processes within the executive branch of that government.
The prohibitions in subsections (a), (b), and (c) above shall include any activity to advocate or promote any proposed, pending, or future Federal, State or local tax increase, or any proposed, pending, or future requirement for, or restriction on, any legal consumer product, including its sale or marketing, including, but not limited to, the advocacy or promotion of gun control.
HHSAR 352.222-70 CONTRACTOR COOPERATION IN EQUAL
EMPLOYMENT OPPORTUNITY (JAN 2010)
SUBMISSION INFORMATION
Proposals must be submitted on an SF-1449 with a completed 52.212-3 Offeror Representations and Certifications-Commercial Items-with DUNS Number Addendum, signed by an authorized representative of the offeror OR provide a copy of valid certification in the System for Award Management (SAM) at www.sam.gov.
Questions must be submitted electronically (via email) to Contract Specialist, Roman Davydov, at roman.davydov@nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than Friday, April 21, 2017, 11:00 am, EST.
Proposals must be submitted electronically (via email) to Contract Specialist, Roman Davydov, at roman.davydov@nih.gov in MS Word or Adobe Portable Document Format (PDF), no later than Monday, May 1, 2017, 11:00 am, EST. All responses must be received by the specified due date and time in order to be considered. PROPOSALS RECEIVED AFTER THIS DATE AND TIME WILL NOT BE CONSIDERED. No collect calls will be accepted.
Please refer to solicitation no: NCI- N02RC73802-53 on all correspondence.
EVALUATION
The award decision will be based on a Lowest Price Technically Acceptable (LPTA) determination. Award will be made on all or none basis. If you are providing an "equal" product, you must submit additional documentation that highlights and describes how your offering is equal in accordance with FAR Clause 52.211-6.
PRICE QUOTE
The Offeror shall prepare a price quote that contains all information necessary to allow for a comprehensive evaluation of the prices quoted. Specifically, your quote must include the following: Federal Tax Identification Number (TIN); Data Universal Numbering System (DUNS) Number; and Business Size (e.g., small or large).
Roman Davydov, Contract Specialist, Phone 301-846-7648, Email roman.davydov@nih.gov - Terry Galloway, Contracting Officer, Phone 301-846-6654, Email gallowaytl@mail.nih.gov
